Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 6,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2019 Filed May 16, 2019 00:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $305.93 | $305,930.00 |
DisclosureSEC source: 0001237899-19-000013 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,323 Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,791 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-19-000007 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,791 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,791 | $410.00 | $734,310.00 |
DisclosureSEC source: 0001237899-19-000007 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,323 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,791 | $273.67 | $490,142.97 |
DisclosureSEC source: 0001237899-19-000007 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-19-000003 · edgardoc.xml · derivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000003 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,323 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 709 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · derivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock · 709 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 709 | $410.00 | $290,690.00 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 709 | $273.67 | $194,032.03 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · derivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $400.00 | $800,000.00 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $273.67 | $547,340.00 |
DisclosureSEC source: 0001708138-18-000024 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · derivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · derivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 1,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $387.29 | $387,290.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $273.67 | $273,670.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $390.00 | $390,000.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $273.67 | $273,670.00 |
DisclosureSEC source: 0001708138-18-000022 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-18-000015 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $380.00 | $760,000.00 |
DisclosureSEC source: 0001708138-18-000015 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $57.11 | $114,220.00 |
DisclosureSEC source: 0001708138-18-000015 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · derivative · entry 6 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $370.00 | $740,000.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · nonDerivative · entry 4 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $57.11 | $114,220.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · nonDerivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · derivative · entry 5 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $360.00 | $720,000.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $57.11 | $114,220.00 |
DisclosureSEC source: 0001708138-18-000011 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001237899-18-000013 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $350.02 | $700,040.00 |
DisclosureSEC source: 0001237899-18-000013 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 2,000 shares of Company stock on March 19, 2018 at prices ranging from $350.00 to $350.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 19, 2018 at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 20:47 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $57.11 | $114,220.00 |
DisclosureSEC source: 0001237899-18-000013 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 14, 2018 Filed Mar 14, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001237899-18-000012 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 14, 2018 Filed Mar 14, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $340.00 | $680,000.00 |
DisclosureSEC source: 0001237899-18-000012 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 14, 2018 Filed Mar 14, 2018 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $57.11 | $114,220.00 |
DisclosureSEC source: 0001237899-18-000012 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $325.60 | $325,600.00 |
DisclosureSEC source: 0001237899-18-000011 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001237899-18-000002 · edgardoc.xml · derivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-17-000009 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 1,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $500.01 | $500,010.00 |
DisclosureSEC source: 0001708138-17-000009 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 20, 2017 at prices ranging from $500.00 to $500.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 20, 2017 at each separate price. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $273.67 | $273,670.00 |
DisclosureSEC source: 0001708138-17-000009 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-17-000018 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 1,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $482.55 | $482,550.00 |
DisclosureSEC source: 0001237899-17-000018 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $273.67 | $273,670.00 |
DisclosureSEC source: 0001237899-17-000018 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000004 · edgardoc.xml · derivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,125 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001237899-16-000083 · edgardoc.xml · derivative · entry 3 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,125 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,125 | $450.00 | $956,250.00 |
DisclosureSEC source: 0001237899-16-000083 · edgardoc.xml · nonDerivative · entry 2 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,125 | $273.67 | $581,548.75 |
DisclosureSEC source: 0001237899-16-000083 · edgardoc.xml · nonDerivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.